Brief Report: Carboplatin, Weekly Paclitaxel and Pembrolizumab in Elderly Patients for Advanced Non-Small Cell Lung Cancer With PD-L1 < 50%: Real-World Data.

IF 4.3 3区材料科学 Q1 ENGINEERING, ELECTRICAL & ELECTRONIC

ACS Applied Electronic Materials Pub Date : 2024-05-18 DOI:10.1016/j.cllc.2024.05.005

引用次数: 0

Abstract

•
Carboplatin, weekly Paclitaxel (CwP) and Pembrolizumab is feasible in patients aged ≥70 with stage IV NSCLC and PD-L1 < 50%
•
Progression-Free Survival and Overall Survival are improved with addition of Pembrolizumab to CwP in this population
•
Toxicity profile is consistent with that of other populations, although with a higher frequency of anemia
•
Addition of Pembrolizumab to CwP should be considered in selected patients aged ≥ 70 with stage IV NSCLC and PD-L1 < 50%

查看原文本刊更多论文

简要报告卡铂、每周紫杉醇和 Pembrolizumab 用于 PD-L1 < 50% 的晚期非小细胞肺癌老年患者：真实世界数据。

-卡铂、每周紫杉醇（CwP）和 Pembrolizumab 可用于年龄≥70 岁的 IV 期 NSCLC 患者，且 PD-L1 <；Pembrolizumab在CwP中的应用提高了无进展生存期和总生存期-毒性特征与其他人群一致，但贫血发生率较高-在CwP中添加Pembrolizumab，应考虑用于年龄≥70岁的IV期NSCLC和PD-L1 <50%的患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Electronic Materials Multiple-

CiteScore

7.20

自引率

4.30%

发文量

567